Pseudoachondroplasia (PSACH) Cell Models for Research

Pseudoachondroplasia (PSACH) is a rare autosomal dominant skeletal dysplasia with an estimated prevalence of 1 in 30,000 to 1 in 60,000 live births (WHO, 2023). It is caused by mutations in the COMP gene (Cartilage Oligomeric Matrix Protein). Clinically, patients present with short-limbed dwarfism, joint laxity, and early-onset osteoarthritis. There is no cure, and management is symptomatic. The disease significantly impacts quality of life and mobility. Research focuses on understanding the molecular mechanisms of COMP mutations and developing targeted therapies.

PSACH is an excellent model for studying protein misfolding, endoplasmic reticulum (ER) stress, and chondrocyte dysfunction. The disease is monogenic, making it amenable to gene editing. Public datasets include ClinVar entries for COMP mutations and GEO expression profiles of patient-derived chondrocytes. Open questions include the precise mechanisms of ER stress-induced apoptosis and the role of COMP in cartilage extracellular matrix assembly.

• • Although PSACH is not a cancer, the pathways involved are relevant to cell stress and survival. Key pathways include:
• • ER stress response (unfolded protein response, UPR)
• • Apoptosis via CHOP and caspase activation
• • Autophagy dysregulation
• • Altered TGF-beta and BMP signaling due to COMP dysfunction

Data from ClinVar and NCBI Gene.

• • COMP mutations lead to ER stress and activation of the UPR. Key nodes include:
• • PERK/eIF2α/ATF4/CHOP axis
• • IRE1α/XBP1 pathway
• • ATF6 pathway
• • NF-κB and inflammatory cytokines
• • Impaired chondrocyte differentiation and matrix production

Organoids derived from patient iPSCs are emerging as more physiologically relevant models, recapitulating cartilage development and disease phenotypes.

• • Genetically engineered mouse models (GEMMs) with Comp mutations (e.g., p.D469del) show dwarfism and ER stress.
• • Induced models using CRISPR to introduce mutations in mice.
• • No PDX models due to non-cancerous nature.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with specific COMP mutations. For example, a COMP knockout line in ATDC5 cells can be used to study loss-of-function effects, while a knock-in of a common mutation (e.g., p.D469del) models the dominant-negative effect. These sequence-verified models are commercially available and accelerate research by providing consistent, reproducible systems for mechanistic studies and drug screening.

Knockout and knock-in lines validate the role of COMP in chondrocyte function. For example, COMP knockout in ATDC5 cells leads to reduced matrix production and altered differentiation. Knock-in of disease mutations allows study of ER stress and apoptosis pathways.

Isogenic pairs (wild-type vs. mutant) are used to screen for compounds that alleviate ER stress or prevent apoptosis. Resistance models can be developed by exposing cells to increasing concentrations of drugs to identify mechanisms of resistance.

CRISPR synthetic lethality screens can identify genes that, when silenced, are lethal in COMP-mutant cells but not wild-type, revealing potential therapeutic targets. Additionally, secretome analysis of mutant cells can identify biomarkers for disease progression.